Williams AO/AC Signals W33 2026 — 24 Signals Across 10 Sectors

Edition 17 · August 14, 2026

W32 Scorecard

🔴 MODEL OUTPUT — Published candidates from last week. No edits. No omissions.

Performance of all Category A candidates named in W32. Prices measured from the Thursday close of W32 (2026-08-07) to the Thursday close of W33 (2026-08-14). Alpha Vantage weekly bars — last bar of the trading week.

Result key: ✓ escalation · ✗ signal lost · — holding/no position. Entry Reference = Thursday close of W32 (2026-08-07). W33 Close = Thursday 2026-08-14. Source: radar.db weekly_bars.

Scorecard summary: 3 escalated · 6 lost signal · 14 holding · 15 of 23 positive · Avg Δ: +1.1% · SPY W32→W33: +0.5%

Exit Analysis — W32 Signals

🔴 MODEL OUTPUT — Did the 6 names that lost signal exit on real appreciation or noise?

Six exits this week — a clean, moderate number that reads very differently from last week's coordinated seven-exit wave. This week's exits are mostly genuine price-driven resolutions, not mass technical resets. The pattern is healthier.

Summary: 3 real appreciation (50%) · 2 range (33%) · 1 without price support or deterioration (17%)

The three energy/materials exits (DVN, LYB, BKR) were genuine — crude conditions improved, oscillators resolved on price. NFLX and FCX cleared on modest gains that do not warrant conviction calls. KR is the lone false signal: the AC flipped technical on a name that actually drifted lower. One false positive out of six is a reasonable week.

Portfolio Tracker

🟢 LIVE POSITIONS — Actual entries with real or paper capital. Updated every week.

Mode: Paper

The Number of the Week

🔴 MODEL OUTPUT

24 active signals across 388 tickers analyzed — 6.2% of the universe.

Signal count held flat this week: 24 versus 23 last week. On the surface that looks like stasis, but the composition changed meaningfully. Last week's list was dominated by XLB carryovers from the W29–W31 build-up, with three S2Ds that were already showing age. This week, four fresh S2D escalations (AMT, UBER, SLB, NEM) replaced the three exits (KR, LYB, DVN), and a significant new name appeared at the top of the quality tier: ISRG, entering at p22% — the highest-quality business in the universe so far this cycle.

A 6.2% signal rate in a market making its 27th record close of the year is a notable divergence. The broad indices are at all-time highs; the model's universe is flagging two dozen names under meaningful compression. That is not contradiction — it is the market telling you where the distribution is wide. The names generating signals this week are not broken businesses. They are dislocated ones.

Follow-Up — W32 Key Names

🔴 MODEL OUTPUT

W33 Candidates — Category A

🔴 MODEL OUTPUT — Algorithm-generated. Not editorial picks.

The 24 tickers the model flagged as priority for W34 monitoring. Ordered by price percentile (lower = more depressed relative to 52-week range).

Decision week: W34 (August 17–21, 2026).

The deep end of the list (p0%–p29%) is dense and persistent. CCI, OLN, AMT, HUN, SNPS, SBAC, ORCL, ISRG, CC, QCOM, DOW — eleven names in the bottom quartile, nine of them at or near structural lows. That kind of bottom-end clustering is the model's way of saying: something is compressed that is not supposed to stay compressed. The question for W34 is whether ISRG's entry into this cluster signals a broader quality rotation beginning, or the first canary in a healthcare sector correction.

S2 Signals — Week 33

🔴 MODEL OUTPUT

Pure S2 — Full Confirmation

None this week.

S2 Degraded — 4 Tickers

Four escalations from S1 this week: AMT, UBER, SLB, NEM. All carry the "degraded" tag because the oscillator is already recovering (green momentum) while AO absolute value remains negative — the AC confirmation arrived just after the most favorable entry point. Still active signals, but the window is narrowing.

Pre-Radar — Approaching the Signal

🔴 MODEL OUTPUT

33 tickers at structural lows (≤p15) with no active signal yet. Names to watch heading into W34.

The XLP consumer staples cluster deserves attention: eight names in the pre-radar (PG, GIS, K, CAG, CPB, TAP, STZ plus a wider beverage/food cohort) with no signal yet. If the oscillator turns in one or two of these simultaneously, that is the kind of sector-level sweep the model occasionally produces after prolonged macro-driven compression. XLC is similarly loaded: TTD at p0%, RBLX at p1%, PARA at p0%, TMUS at p6%. A lot of potential energy building in communication services.

The Universe

388 tickers · 13 sectors Sectors covered: XLU, XLI, XLP, XLE, XLF, XLV, XLB, XLY, XLK, XLC, XLRE, IBB, XBI Market reference: SPY

Active signals by type:

• S1 active: 20
• S2 degraded: 4
• S2 pure: 0
• Tickers at structural lows (≤p15): 12

The Ticker of the Week — Deep Dive

🟡 ANALYST COMMENTARY — Editorial interpretation. Not model output.

ISRG · Intuitive Surgical, Inc.

Why ISRG this week: ISRG enters the signal list for the first time in this cycle — at p22%, near structural lows, after a 38% decline from its January 2025 all-time high of $610. This is the highest-quality business the model has flagged all year. When a company of this caliber appears under compression, it earns a deep dive by default.

The Business

Intuitive Surgical builds, sells, and services robotic-assisted surgical systems. Its flagship da Vinci platform is installed in over 9,000 hospitals globally. The company's revenue model is almost entirely recurring: hospitals pay for the system upfront (capital), then buy disposable instruments and accessories for every procedure performed ($1,500–$3,500 per case), plus annual service contracts. This razor-and-blade structure means that every da Vinci installation is a permanent annuity — one that grows as the installed base deepens procedure utilization year over year.

The da Vinci 5, launched in 2024, carries approximately 11% higher utilization than its predecessor and has driven Q1 2026 da Vinci procedure growth of 16% year over year. The Ion (lung biopsy) and single-port platforms are growing adjacent revenue lines. Q2 2026 adjusted earnings per share of $2.80 beat consensus of $2.48 by 12.9%, and the company raised full-year 2026 procedure growth guidance to 14%–16%. The fundamentals are not in question.

Why Depressed

The stock is down 38% from its peak and sitting at p22% — multi-year lows last seen in early 2024. Two converging forces drove the selloff:

1. Affordable Care Act headwind. The expiry of enhanced tax credits led to a subset of patients losing health insurance coverage in H1 2026, creating a demand-timing headwind for elective robotic procedures. United States da Vinci procedure growth decelerated from 14% in Q1 to 12% in Q2 — still strong in absolute terms, but below what elevated expectations had priced in.

2. Valuation re-rating. ISRG had been priced for perfection at 60–70x forward earnings. When growth moderated even slightly — even with a 12.9% earnings beat — the premium compressed. Wall Street analysts cut price targets; institutional momentum exits accelerated. The stock fell more than 12% after the Q2 report. That drop was sentiment, not fundamentals.

The Setup

The AO reading stands at -90.96, the most negative reading in the entire W33 universe. The oscillator turned negative this week (-6.16), generating an S1 signal. Structurally, ISRG is at p22% — in the bottom quarter of its 52-week range, technically near lows, with a nearLows flag active.

The model is not making a call on when ISRG recovers. It is flagging that the oscillators are in a configuration — deeply oversold, momentum confirming compression — that historically precedes the setup for an S2 pattern. The patient investor framework asks: is this a business whose intrinsic value has declined 38%? The answer is clearly no. Da Vinci 5 is expanding. Procedure volumes are growing at double-digit rates. The recurring revenue model is intact. What has changed is the price.

Risk Factors

• Policy uncertainty around insurance coverage is not resolved. If the structural base of insured patients contracts further, United States procedure volume could face a longer headwind than management projects.
• Competitive pressure from Medtronic's Hugo system and Johnson & Johnson's Ottava is real. Over the medium term, these platforms will take some share in cost-sensitive markets.
• The stock's beta of 1.46 means high market sensitivity. In a broad equity correction, a premium-multiple healthcare name with a mean-reversion narrative will see institutional selling before it sees institutional buying.
• Research and development spend is rising as ISRG invests in next-generation platforms. Margin expansion is not guaranteed in 2026.

The Patient Investor Case

ISRG at $401 is not cheap on a forward price-to-earnings basis — nothing in robotic surgery ever is. But it is cheaper than it has been in two years, on a business that is fundamentally stronger than it was two years ago. The installed base is larger. Da Vinci 5 is out and ramping. Ion and the single-port platform are growing. The procedure model — where every new system compounds future revenue — is intact and expanding.

If the coverage headwind proves temporary (management's base case), United States procedure growth re-accelerates in H2 2026 toward the 14%–16% guidance. That re-acceleration, combined with ongoing international expansion, positions ISRG for another earnings beat cycle that could reprice the stock meaningfully higher. The signal the model just fired is the starting gun for monitoring — not an entry call. That is W34's job.

Manager Note — W33

🟡 ANALYST COMMENTARY — Portfolio manager's macro read. Not model output.

The S&P 500 notched its 27th record close of 2026 this week — and the model responded by flagging 24 names under compression. That divergence is not a contradiction; it is the market doing what markets do at cycle peaks and rotations: lifting the broad index while the distribution within it widens. The winners are winning bigger; the laggards are lagging harder.

What the model is seeing in W33 is a quality tier beginning to emerge within the signal list. ISRG at p22% is the most significant new entry since the cycle began. A business with 16% procedure volume growth, recurring revenue dominance, and a 38%-off price tag does not stay in the bottom quartile of its range indefinitely. The question is not whether ISRG recovers — it is whether the oscillator confirmation arrives before or after the institutional repositioning. That is the information W34 will provide.

The four S2D escalations (AMT, UBER, SLB, NEM) are worth watching collectively. They represent four different macro themes — cell towers, mobility, energy services, gold miners — all resolving technical compression in the same week. That breadth of escalation across unrelated sectors suggests the catalyst is macro, not sector-specific: a broad oscillator reset as the market digests the record-high index print, with individual setups now re-loading for the next move.

Overall stance: constructively cautious. The signals are building in quality names, but none of the S2Ds have pure confirmation, and the pre-radar is loaded with consumer staples and communication services names that have yet to signal. The model is telling you the opportunity set is expanding. The calendar will tell you when to act.

Published: Friday, August 14, 2026